NeuroPace annual stock-based compensation
2020
2021
2022
2023
2024
2025
NeuroPace Stock-Based Compensation Growth & History (NPCE)
NeuroPace's stock-based compensation was $11.1M for fiscal 2025.
View full NeuroPace company overviewNeuroPace annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.1M | $807,000 | +7.85% |
| 2024 | 2024-12-31 | $10.3M | $724,000 | +7.57% |
| 2023 | 2023-12-31 | $9.6M | $1.2M | +14.48% |
| 2022 | 2022-12-31 | $8.3M | $4.1M | +94.71% |
| 2021 | 2021-12-31 | $4.3M | $2.9M | +210.95% |
| 2020 | 2020-12-31 | $1.4M | — | — |
NeuroPace quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.3M | −$925,000 | −28.66% |
| Q1 2026 | 2026-03-31 | $2.3M | −$348,000 | −13.25% |
| Q4 2025 | 2025-12-31 | $2.6M | $4,000 | +0.15% |
| Q3 2025 | 2025-09-30 | $2.6M | $37,000 | +1.43% |
| Q2 2025 | 2025-06-30 | $3.2M | $680,000 | +26.69% |
| Q1 2025 | 2025-03-31 | $2.6M | $86,000 | +3.39% |
| Q4 2024 | 2024-12-31 | $2.6M | $246,000 | +10.44% |
| Q3 2024 | 2024-09-30 | $2.6M | $170,000 | +7.02% |
| Q2 2024 | 2024-06-30 | $2.5M | −$107,000 | −4.03% |
| Q1 2024 | 2024-03-31 | $2.5M | $415,000 | +19.53% |
| Q4 2023 | 2023-12-31 | $2.4M | $281,000 | +13.54% |
| Q3 2023 | 2023-09-30 | $2.4M | $239,000 | +10.95% |
| Q2 2023 | 2023-06-30 | $2.7M | $52,000 | +2.00% |
| Q1 2023 | 2023-03-31 | $2.1M | $637,000 | +42.81% |
| Q4 2022 | 2022-12-31 | $2.1M | $200,000 | +10.66% |
| Q3 2022 | 2022-09-30 | $2.2M | $1.1M | +97.11% |
| Q2 2022 | 2022-06-30 | $2.6M | $1.5M | +135.99% |
| Q1 2022 | 2022-03-31 | $1.5M | $1.3M | +636.63% |
| Q4 2021 | 2021-12-31 | $1.9M | $1.4M | +285.22% |
| Q3 2021 | 2021-09-30 | $1.1M | $806,000 | +267.77% |
| Q2 2021 | 2021-06-30 | $1.1M | $813,000 | +280.34% |
| Q1 2021 | 2021-03-31 | $202,000 | −$99,000 | −32.89% |
| Q4 2020 | 2020-12-31 | $487,000 | — | — |
| Q3 2020 | 2020-09-30 | $301,000 | — | — |
| Q2 2020 | 2020-06-30 | $290,000 | — | — |
| Q1 2020 | 2020-03-31 | $301,000 | — | — |
NeuroPace stock-based compensation trends
Over the last five fiscal years, NeuroPace's stock-based compensation increased from $1.4M to $11.1M, a change of $9.7M. The latest reported quarter, Q2 2026, shows $2.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroPace source filings ↗